Orion Corporation released its earnings results on Jul 17, 2026. The company reported €1 earnings per share for the quarter, beating the consensus estimate of €0.955 by €0.045.

Is Orion Corporation overvalued?

According to Wall Street analysts Orion Corporation’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Orion Corporation pay dividends?

Orion Corporation does not currently pay dividends.

What is Orion Corporation’s EPS estimate?

Orion Corporation’s EPS estimate is 1.1.

How many shares outstanding does Orion Corporation have?

Orion Corporation has 31,373,178 shares outstanding.

What happened to Orion Corporation’s price movement after its last earnings report?

Orion Corporation reported an EPS of €1 in its last earnings report, beating expectations of €0.955. Following the earnings report the stock price went up 12.463%.

Which hedge fund is a major shareholder of Orion Corporation?

Currently, no hedge funds are holding shares in GB:0M2N

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Orion Corporation

Orion Oyj is a globally operating pharmaceutical enterprise engaged in the research, development, manufacturing, and marketing of medicines for both human and animal health, alongside active pharmaceutical ingredients (APIs). Its commercial footprint spans Finland, Scandinavia, other European countries, North America, and numerous international markets. The company's human health portfolio encompasses a variety of prescription drugs and self-care products. Prominent prescription therapies include Nubeqa for prostate cancer; Dexdor and Precedex, utilized as intensive care sedatives; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer. Orion also provides a line of Easyhaler devices, delivering medications such as Salmeterol/fluticasone, Budesonide/formoterol, Formoterol, Budesonide, Beclomet, and Buventol, which are prescribed for the treatment of asthma and chronic obstructive pulmonary disease. For the veterinary segment, Orion manufactures its own drugs like Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie, and also distributes veterinary products from other international companies. Furthermore, the company supplies APIs for both generic and proprietary drug formulations and offers contract manufacturing solutions. Orion's diverse clientele includes healthcare service providers and professionals such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, in addition to consumers who own pets. The company maintains strategic partnerships, including one with Propeller Health to digitally connect its Easyhaler product range for asthma and COPD management, and a research collaboration and license agreement with Alligator Bioscience AB (publ) aimed at discovering and developing novel bispecific antibody cancer therapeutics. Orion Oyj was established in 1917 and is headquartered in Espoo, Finland.